Exencial Wealth Advisors LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Exencial Wealth Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 1.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,716 shares of the biopharmaceutical company’s stock after buying an additional 1,254 shares during the period. Exencial Wealth Advisors LLC’s holdings in Pfizer were worth $1,944,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares during the period. Palacios Wealth Management LLC boosted its position in shares of Pfizer by 1,096.3% in the first quarter. Palacios Wealth Management LLC now owns 256,891 shares of the biopharmaceutical company’s stock worth $6,510,000 after buying an additional 235,417 shares during the period. PrairieView Partners LLC lifted its stake in shares of Pfizer by 47.5% in the first quarter. PrairieView Partners LLC now owns 3,159 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 1,018 shares in the last quarter. Finally, Legacy Capital Group California Inc. lifted its stake in shares of Pfizer by 25.9% in the first quarter. Legacy Capital Group California Inc. now owns 24,939 shares of the biopharmaceutical company’s stock worth $632,000 after acquiring an additional 5,124 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. BMO Capital Markets cut their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $28.44.

Pfizer Stock Down 3.2%

NYSE:PFE opened at $23.95 on Thursday. The firm has a market capitalization of $136.15 billion, a PE ratio of 12.74, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52. The stock has a 50 day moving average of $24.40 and a 200-day moving average of $24.53. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.33% and a net margin of 16.84%. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.